Danish pharmaceutical company Novo Nordisk announced Tuesday the nationwide rollout of a stronger formulation of its popular weight-loss medication Wegovy throughout American pharmacies.
The enhanced version, marketed as Wegovy HD, contains 7.2 milligrams of the active ingredient and received regulatory clearance through the FDA Commissioner’s National Priority Review Voucher program in March.
Previously, the maximum approved strength of the weight-loss injection was limited to 2.4 milligrams.
According to the pharmaceutical manufacturer, patients can obtain the stronger formulation through traditional pharmacies nationwide, the company’s NovoCare Pharmacy network, and approved telehealth services.
Patients paying out-of-pocket for Wegovy HD will face monthly costs of $399, though those with commercial insurance coverage may reduce their expenses to just $25 monthly through the manufacturer’s discount program, the company stated.
In March, Novo Nordisk announced plans to introduce a reduced-price subscription service for American patients purchasing Wegovy without insurance assistance, providing significant cost reductions as the company works to compete with rival Eli Lilly in the expanding obesity treatment marketplace.
